NCT06429150View on ClinicalTrials.gov

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 11, 2024

Primary Completion Date

July 11, 2027

Study Completion Date

December 31, 2027

Conditions
Multiple MyelomaPlasmacytoma
Interventions
BIOLOGICAL

CAR-T cells

Infusion of multi-CAR-T cells

Trial Locations (2)

518000

RECRUITING

Shenzhen Geno-immune Medical Institute, Shenzhen

690105

RECRUITING

Hematologist of the Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health, Vladivostok

All Listed Sponsors
collaborator

The No.2 Clinical Hospital of the Ministry of Health

UNKNOWN

lead

Shenzhen Geno-Immune Medical Institute

OTHER